Updated on 11 December 2012
Dr Dalvir Gill will head TransCelerate BioPharma as its CEO, effective Jan 1, 2013
Singapore: TransCelerate BioPharma has appointed Dr Dalvir Gill as its chief executive officer, effective January 1, 2013. Dr Gill will lead the independent non-profit entity, which was formed by ten healthcare and pharmaceutical companies in September to improve the quality of clinical studies and bring new medicines to patients faster by facilitating the collaboration required to solve common challenges encountered during the clinical trial process.
Dr Gill will succeed Dr Garry Neil, who has served as interim CEO of TransCelerate since the organization was formed in September. Dr Neil will remain as chairman of the board of directors for TransCelerate.
TransCelerate member organizations are currently working together on improving clinical study execution. Under this program, TransCelerate seeks to provide the following solutions for clinical trials: development of a shared user interface for investigator site portals, mutual recognition of study site qualification and training, development of risk-based site monitoring approach and standards, development of clinical data standards, and establishment of a comparator drug supply model.
"I am honored to lead this organization and work with the global research and development community to assess, refine and create processes to bring innovative new medicine to the public faster," said Dr Gill.
Dr Gill has more than 25 years of drug development experience. Prior to his appointment as CEO of TransCelerate, Dr Gill was the president of phase II-IV drug development at PharmaNet-i3, an organization specializing in drug development services. In this role, Dr Gill was responsible for a global business spanning nearly 40 countries.
"Dr Gill is a recognized industry leader with a proven history of success in the field of drug development. His deep experience across the pharmaceutical industry will help TransCelerate to advance key initiatives and provide solutions that will have measurable impact for patients worldwide," said Dr Neil.
Dr Gill earned his BS in Applied Biology from the University of Hertfordshire and his PhD in Pathobiology from the Royal Free Hospital School of Medicine, University of London. He also holds a diploma in the health economics of pharmaceuticals from the executive program of the Stockholm School of Economics. Dr Gill has presented his research and spoken at numerous conferences and has authored over 30 scientific publications. He also is an elected fellow of the Royal Society of Medicine.